Returning investor Tigermed helped the cancer and rare disease therapy developer close a round that will support commercialisation of its Hunter syndrome drug.

Canbridge Pharmaceuticals, a China-based developer of therapeutics for cancer and rare diseases, has closed a $43m series E round featuring clinical and research services provider Hangzhou Tigermed Consulting.

Investment manager 3W Fund Management led the round, which included financial services firm SPD Bank’s SPDBI unit, Casdin Capital, Summer Capital, Yaly Capital and existing backers including Hudson Bay Capital Management, RA Capital Management and Lyfe Capital.

Founded in 2012, Canbridge is working on targeted drug treatments for cancer and additional therapies…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn